Fractyl Laboratories’ mission is to cure metabolic diseases by addressing their root cause: insulin resistance. The company has developed an innovative minimally invasive outpatient approach to treat insulin resistance with a medical device. The device is designed to rejuvenate the lining of the duodenum which leads to a significant decrease in insulin resistance. Currently, the device targets patients with type 2 diabetes, polycystic ovarian syndrome (PCOS) and nonalcoholic steatohepatitis (NASH).
Fractyl’s device is a treatment of the underlying disease and not just its symptoms. Clinical trials are being held in various locations around the world, with promising results, and commercialization has started in Europe..
Potential Oman Impact
Fractyl’s device has yet to be commercialized and is pre-FDA approval however once it has it has great potential globally, including Oman, where there have been almost 100,000 reported cases of diabetes in the sultanate, 80% of which are type 2.
IDO Value Add
IDO offers the unique opportunity for introduction of innovations to a new market – Oman and the GCC. Discussions are already underway with medical stakeholders for Fractyl’s device to be an economic alternative to traditional medication for diabetes and NASH, both of which are prevalent in the region. There has been interest shown, and talks will resume upon commercialization of the products.